AMXT1501/DFMO (polyamine inhibition) therapy
AMXT1501/DFMO (polyamine inhibition) therapy
New decision-making tool for treatment of relapsed and refractory neuroblastoma launched
A brand new support tool developed by Advanced Nurse Practitioner Helen Pearson is now available to parents facing difficult decisions in their child's treatment and care.
Funding award extends clinical trial for children with relapsed or refractory neuroblastoma
We're pleased to announce the extension of funding for the MiNivAn trial, investigating new combination therapies for children with relapsed or refractory high-risk neuroblastoma.
Solving Kids’ Cancer UK announces three-year charity partnership with Julius Baer International Ltd
Solving Kids’ Cancer UK is proud to announce a new three-year charity partnership with Julius Baer International Ltd, the UK entity of one of the world’s leading wealth management firms.
New funding for Senior Trial Coordinator post at Cancer Research Clinical Trials Unit
Solving Kids’ Cancer UK are pleased to announce renewed funding for the Cancer Research Clinical Trials Unit (CRCTU) at the University of Birmingham.
Charities come together for Teenage and Young Adult Cancer Awareness Month
This April, we're uniting with charities to raise awareness of the unique challenges facing young people when diagnosed with cancer.
ACCELERATE 2024: A round-up
An update from the research team on their recent trip to Brussels for the ACCELERATE annual conference.
Collaboration aims to improve outcomes for children with neuroblastoma
Solving Kids’ Cancer UK and Neuroblastoma UK have entered into a formal collaboration to speed up the development of new, better treatments for children with neuroblastoma.
Solving Kids’ Cancer UK’s response to government announcement of Childhood Cancer Taskforce
Solving Kids' Cancer UK responds to the announcement of a government-led Childhood Cancer Taskforce
